166 related articles for article (PubMed ID: 31168770)
1. Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children.
Hagos FT; Horvat CM; Au AK; Conley YP; Li L; Poloyac SM; Kochanek PM; Clark RSB; Empey PE
Clin Pharmacokinet; 2019 Dec; 58(12):1567-1576. PubMed ID: 31168770
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Fentanyl in the Critically Ill.
Choi L; Ferrell BA; Vasilevskis EE; Pandharipande PP; Heltsley R; Ely EW; Stein CM; Girard TD
Crit Care Med; 2016 Jan; 44(1):64-72. PubMed ID: 26491862
[TBL] [Abstract][Full Text] [Related]
3. ABCB1 genotype is associated with fentanyl requirements in critically ill children.
Horvat CM; Au AK; Conley YP; Kochanek PM; Li L; Poloyac SM; Empey PE; Clark RSB
Pediatr Res; 2017 Jul; 82(1):29-35. PubMed ID: 28388599
[TBL] [Abstract][Full Text] [Related]
4. Characterizing Fentanyl Variability Using Population Pharmacokinetics in Pediatric Burn Patients.
Grimsrud KN; Lima KM; Tran NK; Palmieri TL
J Burn Care Res; 2020 Jan; 41(1):8-14. PubMed ID: 31538188
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic model of subcutaneous fentanyl in older acute care patients.
Al-Qurain AA; Upton R; Williams DB; Mackenzie L; Phillips C; Russell PT; Tadros R; Roberts MS; Wiese MD
Eur J Clin Pharmacol; 2021 Sep; 77(9):1357-1368. PubMed ID: 33811491
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population.
Williams ML; Kannankeril PJ; Breeyear JH; Edwards TL; Van Driest SL; Choi L
Clin Pharmacol Ther; 2022 Apr; 111(4):896-908. PubMed ID: 34877660
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients.
Bartkowska-Śniatkowska A; Bienert A; Wiczling P; Rosada-Kurasińska J; Zielińska M; Warzybok J; Borsuk A; Tibboel D; Kaliszan R; Grześkowiak E
J Clin Pharmacol; 2016 Jan; 56(1):109-15. PubMed ID: 26105145
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of continuous infusions of fentanyl in critically ill children.
Katz R; Kelly HW
Crit Care Med; 1993 Jul; 21(7):995-1000. PubMed ID: 8319480
[TBL] [Abstract][Full Text] [Related]
9. Clinical sedation scores as indicators of sedative and analgesic drug exposure in intensive care unit patients.
Masica AL; Girard TD; Wilkinson GR; Thomason JW; Truman Pun B; Nair UB; Light RW; Canonico AE; Dunn J; Pandharipande P; Shintani AK; Ely EW
Am J Geriatr Pharmacother; 2007 Sep; 5(3):218-31. PubMed ID: 17996661
[TBL] [Abstract][Full Text] [Related]
10. Effect of low-dose naloxone infusion on fentanyl requirements in critically ill children.
Darnell CM; Thompson J; Stromberg D; Roy L; Sheeran P
Pediatrics; 2008 May; 121(5):e1363-71. PubMed ID: 18411237
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.
Ziesenitz VC; Vaughns JD; Koch G; Mikus G; van den Anker JN
Clin Pharmacokinet; 2018 Feb; 57(2):125-149. PubMed ID: 28688027
[TBL] [Abstract][Full Text] [Related]
12. Pragmatic pharmacology: population pharmacokinetic analysis of fentanyl using remnant samples from children after cardiac surgery.
Van Driest SL; Marshall MD; Hachey B; Beck C; Crum K; Owen J; Smith AH; Kannankeril PJ; Woodworth A; Caprioli RM; Choi L
Br J Clin Pharmacol; 2016 Jun; 81(6):1165-74. PubMed ID: 26861166
[TBL] [Abstract][Full Text] [Related]
13. A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach.
Encinas E; Calvo R; Lukas JC; Vozmediano V; Rodriguez M; Suarez E
Paediatr Drugs; 2013 Jun; 15(3):247-57. PubMed ID: 23657896
[TBL] [Abstract][Full Text] [Related]
14. Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients.
Oosten AW; Abrantes JA; Jönsson S; de Bruijn P; Kuip EJ; Falcão A; van der Rijt CC; Mathijssen RH
Eur J Clin Pharmacol; 2016 Apr; 72(4):459-67. PubMed ID: 26762381
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain.
Kaessner N; Nave R; Roepcke S; Facius A; Lahu G
Int J Clin Pharmacol Ther; 2012 Sep; 50(9):665-77. PubMed ID: 22784611
[TBL] [Abstract][Full Text] [Related]
16. Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics: A Pilot Study.
Grimsrud KN; Ivanova X; Sherwin CM; Palmieri TL; Tran NK
J Burn Care Res; 2019 Jan; 40(1):91-96. PubMed ID: 30371861
[TBL] [Abstract][Full Text] [Related]
17. Analysis of fentanyl pharmacokinetics, and its sedative effects and tolerance in critically ill children.
Lim SY; Miller JL; Henry E; Heltsley R; Woo S; Johnson PN
Pharmacotherapy; 2021 Apr; 41(4):359-369. PubMed ID: 33604895
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.
Jin M; Gock SB; Jannetto PJ; Jentzen JM; Wong SH
J Anal Toxicol; 2005 Oct; 29(7):590-8. PubMed ID: 16419387
[TBL] [Abstract][Full Text] [Related]
19. Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis.
Kos MK; Miksić M; Jovanović M; Roškar R; Grosek Š; Grabnar I
Eur J Pharm Sci; 2020 Jan; 141():105095. PubMed ID: 31626965
[TBL] [Abstract][Full Text] [Related]
20. Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates.
Collins JJ; Dunkel IJ; Gupta SK; Inturrisi CE; Lapin J; Palmer LN; Weinstein SM; Portenoy RK
J Pediatr; 1999 Mar; 134(3):319-23. PubMed ID: 10064669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
